The UK’s Medicines and Healthcare products Regulatory Agency has approved Leqembi, an Alzheimer’s drug developed by Eisai and Biogen, for treating early-stage Alzheimer’s disease. However, the National Institute for Health and Care Excellence (NICE) has declined to recommend the drug for use on the NHS due to its high cost and limited benefits.